Conference Summary


press release date: May 8 , 2008
for quarter ending: March 31, 2008 (1st quarter)

I own this
Forward-looking statements

Overview: No analyst conference held. Financials in line with my expectations. Waiting for enough events in the Provenge trial to get the interim data.

Basic data:

Revenue was $31,000.

Net loss was $19.5 million.

EPS loss was $0.23 million.

$99.6 million in cash and equivalents.



Press Release Highlights:

"FDA agreed to amend the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) SPA, accelerating the expected timeline for final results from the study by approximately one year while maintaining comparable power to the previous SPA. In addition, the FDA reconfirmed that either a positive interim or final analysis of survival would support licensure and enable Dendreon to amend the Company's biologics license application for PROVENGE."

Neuvenge Phase I study showed it may be beneficial in breast, colorectal, and ovarian cancer.

Stock offering generated $46 million in cash, which should be enough to finish the IMPACT study.


No conference held

Dendreon Main Page
Dendreon corporate investor page
OpenIcon Analyst Conference Summaries Main Page



More Analyst Conference Pages:


Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2008 William P. Meyers